Pyran template approach to the design of novel A3 adenosine receptor antagonists

被引:0
|
作者
Li, AH [1 ]
Ji, XD [1 ]
Kim, HS [1 ]
Melman, N [1 ]
Jacobson, KA [1 ]
机构
[1] NIDDK, LBC, Mol Recognit Sect, NIH, Bethesda, MD 20892 USA
关键词
G protein-coupled receptors; structure-activity relationships; template; radioligand binding; purines;
D O I
10.1002/(SICI)1098-2299(199912)48:4<171::AID-DDR4>3.0.CO;2-5
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A(3) adenosine receptor antagonists have potential as anti-inflammatory, anti-asthmatic, and anti-ischemic agents. We previously reported the preparation of chemical libraries of 1, 1-dihydropyridine (DHP) and pyridine derivatives and identification of members having high affinity at A(3) adenosine receptors. These derivatives were synthesized through standard three-component condensation/oxidation reactions, which permitted versatile ring substitution at five positions, i.e., the central ring served as a molecular scaffold for structurally diverse substituents. We extended this template approach from the DHP series to chemically stable pyran derivatives, in which the ring NH is replaced by O and which is similarly derived from a stepwise reaction of three components. Since the orientation of substituent groups may be conformationally similar to the 1,4-DH Ps, a direct comparison between the structure activity relationships of key derivatives in binding to adenosine receptors was carried out. Affinity at human Ag receptors expressed in CHO cells was determined vs, binding of [I-125]AB-MECA (N-6-(4-amino-3-iodobenzyl)-5'-N-methyl-carbamoyladenosine). There was no potency-enhancing effect, as was observed for DHPs, of 4-styryl, 4-phenylethynyl, or 6-phenyl substitutions. The most potent ligands in this group in binding to human A(3) receptors were 6-methyl and 6-phenyl analogs, 3a (MRS 1704) and 4a (MRS 1705), respectively, of 3,5-diethyl 2-methyl-4-phenyl-4H-pyran-3,5-dicarboxy which had K-i values of 381 and 583 nM, respectively. These two derivatives were selective for human A3 receptors vs. rat brain A(1) receptors by 57-fold and 24-fold, respectively. These derivatives were inactive in binding at rat brain A(2A) receptors, and at recombinant human A(2B) receptors displayed K-i values of 17.3 and 23.2 mu M, respectively. The selectivity, but not affinity of the pyran derivatives in binding to the A(3) receptor subtype was generally enhanced vs. the corresponding DHP derivatives. Drug Dev. Res. 48:171-177, 1999. Published 1999 Wiley-Liss, Inc.(+)
引用
收藏
页码:171 / 177
页数:7
相关论文
共 50 条
  • [21] Binding affinity of adenosine receptor agonists and antagonists at human cloned A3 adenosine receptors
    Varani, K
    Cacciari, B
    Baraldi, PG
    Dionisotti, S
    Ongini, E
    Borea, PA
    LIFE SCIENCES, 1998, 63 (05) : PL81 - PL87
  • [22] Pharmacological characterization of DPTN and other selective A3 adenosine receptor antagonists
    Gao, Zhan-Guo
    Suresh, R. Rama
    Jacobson, Kenneth A.
    PURINERGIC SIGNALLING, 2021, 17 (04) : 737 - 746
  • [23] Synthesis and biological activities of flavonoid derivatives as A3 adenosine receptor antagonists
    Karton, Y
    Jiang, JL
    Ji, XD
    Melman, N
    Olah, ME
    Stiles, GL
    Jacobson, KA
    JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (12) : 2293 - 2301
  • [24] Isoquinoline and quinazoline urea analogues as antagonists for the human adenosine A3 receptor
    van Muijlwijk-Koezen, JE
    Timmerman, H
    van der Goot, H
    Menge, WMPB
    Künzel, JFV
    de Groote, M
    IJzerman, AP
    JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (11) : 2227 - 2238
  • [25] NUCLEOSIDE-BASED ADENOSINE A3 RECEPTOR ANTAGONISTS AS DRUG CANDIDATES
    Tosh, D. K.
    Jacobson, K. A.
    Jeong, L. S.
    DRUGS OF THE FUTURE, 2009, 34 (01) : 43 - 52
  • [26] Recent developments in the field of A2A and A3 adenosine receptor antagonists
    Baraldi, PG
    Tabrizi, MA
    Bovero, A
    Avitabile, B
    Preti, D
    Fruttarolo, F
    Romagnoli, R
    Varani, K
    Borea, PA
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2003, 38 (04) : 367 - 382
  • [27] New highly potent and selective adenosine A3 receptor antagonists.
    Press, NJ
    Fozard, JR
    Beer, D
    Heng, R
    di Padova, F
    Tranter, P
    Trifilieff, A
    Walker, C
    Keller, TH
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2002, 224 : U79 - U80
  • [28] Pharmacological characterization of DPTN and other selective A3 adenosine receptor antagonists
    Zhan-Guo Gao
    R. Rama Suresh
    Kenneth A. Jacobson
    Purinergic Signalling, 2021, 17 : 737 - 746
  • [29] Evaluation Of Novel A3 Adenosine Receptor Agonist In Hypertension
    Zapata-Sudo, Gisele
    Rocha, Bruna
    Da Silva, Jaqueline S.
    Montagnoli, Tadeu
    Pedreira, Julia G.
    Barreiro, Eliezer J.
    CIRCULATION RESEARCH, 2023, 133
  • [30] Characterization of Novel A3 Adenosine Receptor Allosteric Modulators
    Fisher, Courtney L.
    Wan, Tina C.
    Fallot, Lucas B.
    Keyes, Robert F.
    Suresh, R. R.
    Rothwell, Amy C.
    Gao, Zhan-Guo
    McCorvy, John D.
    Smith, Brian C.
    Jacobson, Kenneth A.
    Auchampach, John A.
    FASEB JOURNAL, 2022, 36